Kiora Pharmaceuticals, Inc. (KPRX)

Market Cap	11.88M +22.5%
Revenue (ttm)	n/a
Net Income	-11.06M
EPS	-2.66
Shares Out	4.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,443
Open	2.750
Previous Close	2.830
Day's Range	2.700 - 2.830
52-Week Range	1.765 - 4.180
Beta	-0.47
Analysts	Buy
Price Target	12.00 (+344.44%)
Earnings Date	May 8, 2026

About KPRX

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the tre...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: KPRX
• Website: https://www.kiorapharma.com

Analyst Summary

According to one analyst, the rating for KPRX stock is "Buy" and the 12-month stock price target is $12.0.

Price Target

$12.0

(344.44% upside)

Analyst Consensus: Buy